These data indicate that analyzing MAGE-C1/CT7-transcript concentration correlates with PFS but does not result in survival in patients with multiple myeloma receiving triplet induction therapy including a proteasome inhibitor and an ASCT as initial therapy. Here, MAGEC1 is linked to AL amyloidosis.